Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press4310.17650/1726-9784-2015-14-4-53-58ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯTOXICOLOGICAL PROPERTIES OF BIOMODIFIED ENZYME DRUG - L-ASPARAGINASE WAS79ТОКСИКОЛОГИЧЕСКАЯ ХАРАКТЕРИСТИКА БИОМОДИФИІДОРОВАІIIІОІ О ФЕРМЕНТНОГО ПРЕПАРАТА - L-АСПАРАГИНАЗЫ WAS79PereverzevaE. R.ПереверзеваЭлеонора Рафаиловна
Russian Federation
pereverzeva-ella@vandex.ruTreschalinI. D.ТрещалинИ. Д.
Russian Federation
VoznyakovskayaE. V.ВозняковскаяЕ. В.
Russian Federation
TreschalinM. I.ТрещалинМ. М.
Russian Federation
PereverzevaT. B.ПереверзеваТ. Б.
Russian Federation
EremkinN. V.ЕремкинИ. В.
Russian Federation
BulushovaN. V.БулушоваИ. В.
Russian Federation
SannikovaE. P.СанниковаЕ. М.
Russian Federation
Gause Institute of New AntibioticsФГБНУ «НИИНА им. Г.Ф. Гаузе»Research Institute of Genetics and SelectionФГУП ГосНИИгенетики30122015144535810042018https://bioterapevt.abvpress.ru/jour/article/view/43

Toxicological study of L-asparaginase Was79, obtained by modification of native enzyme Wolinella succinogenes in Research Institute of Genetics and Selection, was performed in male and female inbred rats. L-asparaginase was injected intraperitoneally at the 1 and 10 therapeutic dose (15x1200 IU/kg or 15x12000 IU/kg with 24-h interval). Dynamics of body weight, hematological parameters, blood biochemical parameters, electrocardiography and urinalysis were performed for all animals. Five animals in each group were sacrificed 1 and 15 days post treatment. At necropsy, the organs were inspected macroscopically. The mass coefficients of heart, kidneys, liver, spleen and thymus were calculated. The pathomorphological evaluation was performed for internal organs. The results of the study demonstrate that the treatment with L-asparaginase Was79 did not produce any changes in body weight, hematology, blood biochemical or urinary parameters. Hematological, renal, gastrointestinal, and pancreatic toxicity of L-asparaginase have been documented only by microscopic pathology observation. Liver toxicity, revealed in the histopathological findings, was supported by the results of clinical chemistry. Marked elevation of ALT and alkaline phosphatase in serum was found in both treated groups. Most of these abnormalities were reversible and dose-dependent.

L-аспарагиназаWolinella succinogenesхроническая токсичностькрысыL-asparaginaseWolinella succinogeneschronic toxicityratsРуководство по проведению доклинических исследований лекарственных средств / Под ред. А.Н. Миронова. - М.: Гриф и К, 2012. - 4.1. -С. 13-24.Соколов М.А., Эльдаров М.В. Покровская С.С. и др. Бактериальные рекомбинантные l-аспарагиназы: свойства, строение и антипролиферативная активность // Биомедицинская химия. - 2015. - Т. 61, № 3. - С. 312-24.Bendich A., Kafkewitz !)., Abuchowsld A., Davis F.F. Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice // Clin. Exp. Immunol. - 1982.-48.-P. 273-8.Derst C., Henseling J., Rohm K.H. Engineering the substrate specificity of Escherichia coli asparaginase II. Selective reduction of glutaminase activity by amino acid replacements at position // Protein Science. - 2000. - P. 2009-17.Distasio J.A., Niederman R.A., Kafkewitz D., Goodman D. Purification and characterization of 1-asparaginase with antilymphoma activity from Vibrio succinogenes // J. Biol. Chem. - 1976. - 251(69). - P. 29-33.Distasio J.A., Niederman R.A., Kafkewitz D. Antilymphoma activity of a glutaminase-free L-asparaginase of microbial origin // Exp Biol Med. - 1977. - 155(26). - P. 528-31.Distasio J.A., Salazar A.M., Nadji M., Durden D.L. Glutaminase-Free Asparaginase From Vibrio Succinogenes: An Antilymphoma Enzyme Lacking Hepatotoxicity // Znt. J. Cancer. - 1982. - 30. - P. 343-7.Durden D.L., Distasio J.A. Characterization of the effects of asparaginase from Escherichia coli and a glutaminase free asparaginase from Vibrio succinogenes on specific cell-mediated cytotoxicity // Int. J. Cancer. - 1981. - 27. - P. 59-65.Durden D.L., Salazar A.M., Distasio J.A. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases // Cancer Res. - 1983. - 43. - P. 1602-5.European Convention for the protection of vertebrate animals used for experimental and other scientific purposes (Council of Europe, ETS No. 123).-1986.Freireich E.J., Gehan E.A., Rail D.P. et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey and man // Cancer Chemother. Repts. - 1966. - 50(4). - P. 219-44.Haskell S.M., Canellos G.P., Leventhal B.G. et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease //New Engl. J. Med. - 1969. - 281. - P. 1028-34.Khan A., AdachiM., Hill J.M. Diabetogenic effect of L-asparaginase // J. Clin. Endocrinol. & Metab. - 1969. - 29. - P. 1373-9.Lubkowski J., Palm G.J., Gilliland G.L. et al. Crystal structure and amino acid sequence of Wolinella succinogenes L- asparaginase//Eur. J. Biochem. - 1996. -241. -P. 201-7.Ollenschlager G^ Roth E., Linkesch W. et al. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects //Eur. J. Clin. Invest. - 1988. - 18(5). -P. 512-6.Plourde P. V, Jeha S., Hijiya N. et al. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial // Pediatric Blood & Cancer. - 2014. - 61(7). -_P. 1232-8.Reinert R.B., Oberle L.M., Wek S.A. et al. Role Of Glutamine Depletion In Directing Tissue-Specific Nutrient Stress Responses To L-Asparaginase // J. Biol. Chem. - 2006. - 281. -P. 31222-33.Storti E., Quaglino D. Dysmetabolic and neurologic complications in leukemic patients treated with L-asparaginase. In Experimental and clinical Effects of L-asparaginase. New York, Springer-Verlang, 1970. - P. 344-9.Wintrobe MM. Clinical hematology, ed. 6, - Philadelphia, Lea & Febiger, 1969. - P. 1044.Zubrod C.G. The clinical toxicities of L-asparaginase in treatment of leukemia and lymphoma // Pediat. - 1970. - 45. - P. 555-9.